High-intensity immunohistochemistry results demonstrated that SRPK1 is positively associated with poor prognosis in grade III gliomas (HR = 2.01, 95% CI 1.47–2.30, p = 0.026) and grade IV gliomas (HR = 1.92, 95% CI 1.38–2.25, p = 0.017) (Figure 1E). Here, SRPK1 is linked to central nervous system cancer.